Robinson Smith Wealth Advisors LLC Makes New $1.03 Million Investment in IDEXX Laboratories, Inc. $IDXX

Robinson Smith Wealth Advisors LLC acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the third quarter, HoldingsChannel reports. The institutional investor acquired 1,969 shares of the company’s stock, valued at approximately $1,028,000.

Other large investors also recently modified their holdings of the company. Bank of New York Mellon Corp purchased a new stake in shares of IDEXX Laboratories during the second quarter worth about $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of IDEXX Laboratories by 4.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after acquiring an additional 39,700 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of IDEXX Laboratories by 52.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after acquiring an additional 288,471 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in IDEXX Laboratories by 4.3% in the first quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock valued at $322,145,000 after purchasing an additional 23,582 shares during the last quarter. Finally, Alyeska Investment Group L.P. boosted its holdings in IDEXX Laboratories by 97.3% in the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after purchasing an additional 197,808 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.79% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on IDXX shares. The Goldman Sachs Group assumed coverage on IDEXX Laboratories in a research note on Friday, October 16th. They set a “buy” rating and a $740.00 price objective for the company. Barclays cut their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Citigroup increased their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Weiss Ratings raised shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Finally, KeyCorp began coverage on shares of IDEXX Laboratories in a research report on Monday, October 12th. They set a “sector weight” rating for the company. Seven analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus target price of $744.09.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $566.76 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. IDEXX Laboratories, Inc. has a one year low of $500.61 and a one year high of $769.98. The company’s 50-day simple moving average is $532.51 and its 200-day simple moving average is $551.58. The stock has a market capitalization of $44.65 billion, a price-to-earnings ratio of 39.86, a PEG ratio of 2.96 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. IDEXX Laboratories’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the previous year, the company earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.